[{"id":"ae36f3a0-eb85-44ba-afee-09efb5463d1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01434316","created_at":"2021-01-18T05:55:48.375Z","updated_at":"2025-02-25T16:51:08.574Z","phase":"Phase 1","brief_title":"Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01434316","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • RAD51","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • dinaciclib (MK-7965)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/11/2011","start_date":" 11/11/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-04"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"e3281842-d356-4140-b072-e185ef794324","acronym":"SkinHealthOnco","url":"https://clinicaltrials.gov/study/NCT05878964","created_at":"2023-05-30T14:05:01.901Z","updated_at":"2024-07-02T16:35:15.487Z","phase":"","brief_title":"Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.","source_id_and_acronym":"NCT05878964 - SkinHealthOnco","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"],"overall_status":"Recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 07/22/2024","primary_completion_date":" 07/22/2024","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-03-11"},{"id":"efa29a1e-2944-49b3-b0e3-5e8f2332ce4a","acronym":"NCI-2018-01053","url":"https://clinicaltrials.gov/study/NCT01676753","created_at":"2021-01-18T07:15:38.079Z","updated_at":"2025-02-25T16:02:39.035Z","phase":"Phase 1b","brief_title":"Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer","source_id_and_acronym":"NCT01676753 - NCI-2018-01053","lead_sponsor":"Jo Chien","biomarkers":" PGR","pipe":" | ","alterations":" PGR expression","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • dinaciclib (MK-7965)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 12/28/2016","start_date":" 12/28/2016","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2022-09-21"},{"id":"0abd8fc1-b9bb-47ad-887a-ea2d0e5abad8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03850873","created_at":"2021-01-18T19:00:47.644Z","updated_at":"2024-07-02T16:37:02.527Z","phase":"Phase 1","brief_title":"A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics","source_id_and_acronym":"NCT03850873","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Saitanxin (culmerciclib)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2019-02-22"},{"id":"07bce700-fe42-4bb9-aa13-93f6cdc1621a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01624441","created_at":"2021-01-18T06:58:11.122Z","updated_at":"2024-07-02T16:37:12.599Z","phase":"Phase 1","brief_title":"Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT01624441","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • MCL1","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • ER • PGR • MCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epirubicin • dinaciclib (MK-7965)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/21/2012","start_date":" 08/21/2012","primary_txt":" Primary completion: 09/10/2013","primary_completion_date":" 09/10/2013","study_txt":" Completion: 09/10/2013","study_completion_date":" 09/10/2013","last_update_posted":"2018-03-30"},{"id":"d694717e-b927-4af3-9e74-7306f9efff05","acronym":"","url":"https://clinicaltrials.gov/study/NCT01188252","created_at":"2021-01-18T04:45:06.986Z","updated_at":"2025-02-25T17:18:29.403Z","phase":"Phase 1","brief_title":"Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01188252","lead_sponsor":"Bayer","biomarkers":" CASP3 • CDKN1A • ANXA5","pipe":" | ","alterations":" MCL1 expression","tags":["CASP3 • CDKN1A • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e roniciclib (BAY1000394)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-09"},{"id":"274b6789-cafa-442a-b349-5cb43132ed40","acronym":"","url":"https://clinicaltrials.gov/study/NCT02656849","created_at":"2021-01-18T12:56:12.287Z","updated_at":"2025-02-25T17:23:00.771Z","phase":"Phase 2","brief_title":"BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors","source_id_and_acronym":"NCT02656849","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • CCNE1 • MCL1","pipe":" | ","alterations":" MYC amplification • CCNE1 amplification • MCL1 amplification","tags":["MYC • CCNE1 • MCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC amplification • CCNE1 amplification • MCL1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e roniciclib (BAY1000394)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2016-07-01"}]